Document is current
Any future updates will be listed below
-
Authors
Arnold, Shanna A.
Loomans, Holli A.
Ketova, Tatiana
Andl, Claudia D.
Clark, Peter E.
Zijlstra, Andries https://orcid.org/0000-0001-8460-8803
-
Funding
Funding for this research was provided by:
National Institutes of Health (CA9060625)
National Center for Advancing Translational Sciences (UL1-TR000445)
National Cancer Institute (CA009593)
National Cancer Institute (CA143081)
National Cancer Institute (CA040035)
National Institute of Diabetes and Digestive and Kidney Diseases (DK094900)
National Institute of Diabetes and Digestive and Kidney Diseases (DK091491)
Office of Research and Development (IK2BX002498)
- License Information
-
More Information
Article History
Received: 24 March 2015
Accepted: 1 October 2015
First Online: 11 October 2015
Compliance with ethical standards
:
: This article does not contain any studies with animals performed by any of the authors.
: The authors have no competing interests to disclose.
: Despite improvements in the detection and treatment of bladder cancer (BCa), few advances have been made in predicting outcome and non-invasively monitoring disease progression. We show that the ED-A isoform of fibronectin and not total fibronectin is a prognostic urinary biomarker in BCa. Furthermore, the greatest discrimination with urinary ED-A occurs in lymph node negative patients where those with undetectable levels of urinary ED-A are 10 times more likely to survive 2 years following cystectomy compared to those with any detectable level of urinary ED-A.
